Clinical Trial

A Phase I, First-in-Human Study of GB268 (PD-1/CTLA-4/VEGF Trispecific Antibody) in Advanced Solid Tumors

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase I, First-in-Human, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of a Trispecific PD-1/CTLA-4/VEGF Antibody GB268 in Participants with Advanced Solid Tumors. The study will consist of a dose-escalation stage and an dose-expansion stage.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-11.
Trial Details
NCT Number NCT06934616
Lead Sponsor Genor Biopharma Co., Ltd.
Conditions Solid Tumor Cancer
Enrollment 330 participants
Start Date 2025-04-24
Primary Completion 2027-03 (estimated)
Study Completion 2028-03 (estimated)
Updated on ClinicalTrials.gov 2025-04-30